358970-97-5 Usage
Description
Drinabant, also known as AVE-1625, is a highly potent and selective antagonist for the CB1 receptor. It is a G protein-coupled receptor antagonist that is widely distributed in the central nervous system and several peripheral tissues. Drinabant binds to the active component of cannabis, Δ9-tetrahydrocannabinol, and is known for its potential effects on attentional and working memory deficits as well as obesity.
Uses
Used in Pharmaceutical Industry:
Drinabant is used as a therapeutic agent for addressing attentional and working memory deficits. It has been shown to significantly improve the performance of rodents in working memory tasks at doses of 1-3 mg/kg.
Used in Obesity Treatment:
Drinabant is used as an obesity treatment agent. At a dose of 30 mg/kg, it has been demonstrated to reduce caloric intake by more than 50% of controls and significantly increase lipolysis from fat tissues, as well as reduce hepatic glycogen levels in rodents. This suggests its potential use in the development of anti-obesity drugs.
Used in Research Applications:
Drinabant is also used as a research tool for studying the role of the CB1 receptor in various physiological and pathological processes. Its high potency and selectivity make it a valuable compound for investigating the mechanisms underlying memory, attention, and energy balance regulation.
references
[1] borowsky b, stevens r, mark b, et al. ave1625, a cannabinoid cbi antagonist, as a co-treatment for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in animal models[c]//neuropsychopharmacology. macmillan building, 4 crinan st, london n1 9xw, england: nature publishing group, 2005, 30: s116-s117.[2] herkenham m, lynn a b, little m d, et al. cannabinoid receptor localization in brain[j]. proceedings of the national academy of sciences, 1990, 87(5): 1932-1936.[3] herling a w, gossel m, haschke g, et al. cb1 receptor antagonist ave1625 affects primarily metabolic parameters independently of reduced food intake in wistar rats[j]. american journal of physiology-endocrinology and metabolism, 2007, 293(3): e826-e832.
Check Digit Verification of cas no
The CAS Registry Mumber 358970-97-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,8,9,7 and 0 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 358970-97:
(8*3)+(7*5)+(6*8)+(5*9)+(4*7)+(3*0)+(2*9)+(1*7)=205
205 % 10 = 5
So 358970-97-5 is a valid CAS Registry Number.
358970-97-5Relevant articles and documents
Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia
-
Page/Page column 11, (2008/12/08)
-
METHOD AND INTERMEDIATES FOR THE PREPARATION OF DERIVATIVES OF N (1-BENZHYDRYLAZETIDIN-3-YL)-N-PHENYLMETHYLSULFONAMIDE
-
Page/Page column 7, (2008/06/13)
The invention relates to a novel method for the synthesis of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.
